AOD-9604
Anti-obesity drug 9604, Lipotropin
The one compound in this corner of the market that was properly tested as an obesity drug, in an adequately powered phase 2b trial, and failed it.
Preclinical only
Not approved. Development for obesity was terminated in 2007 after the pivotal trial missed its endpoint. Later granted GRAS status as a food ingredient in the United States, which is a food safety determination and not a finding of efficacy.
What it is
AOD-9604 is a stabilised analogue of the C-terminal fragment of growth hormone, residues 176 to 191, with a tyrosine added to improve stability. It was developed by Metabolic Pharmaceuticals in Australia on the premise that this region carries growth hormone's fat-metabolising activity without its growth-promoting effects.
The trial that settled it
This is the rare compound in this space with a properly conducted, adequately powered, placebo-controlled trial designed to answer the question people actually care about.
A twelve week study looked promising: roughly 2.6 kg lost against 0.8 kg on placebo. The confirmatory phase 2b ran 24 weeks in 536 subjects. The best dose group lost about 2.6 kg against 1.8 kg on placebo, a difference that was not statistically significant.
Development stopped in 2007.
The primary phase 2b publication was never submitted to a peer-reviewed journal. That absence is worth naming: the encouraging twelve week result is easy to find and cite, and the larger trial that failed to confirm it is not in the literature at all. Anyone researching this compound from published sources alone would come away with a systematically misleading picture.
What happened afterwards
AOD-9604 later obtained GRAS status in the United States as a food ingredient. This gets cited in marketing as though it were a regulatory endorsement.
It is not. GRAS is a determination that a substance is generally recognised as safe for consumption. It says nothing whatever about whether the substance does anything, and a compound that failed to beat placebo on weight loss is exactly the sort of thing that can be safe and inert simultaneously.
The joint indication is a separate and thinner story
A second line of research looked at intra-articular AOD-9604 for cartilage, including a rabbit osteoarthritis model with and without hyaluronic acid. This is where the current marketing for joint health originates.
It is animal work, delivered by injection directly into the joint, which is not what anyone selling subcutaneous vials is proposing.
Practical notes
- The negative trial is the single most important fact about this compound and it is almost never mentioned. If a vendor page cites the twelve week study and stops there, that is the tell.
- Route and dose in practice match nothing that was studied. The obesity trials were oral. Reported practice is subcutaneous at a fraction of the dose.
- Safety is not the objection here. Efficacy is. This appears to be a well-tolerated compound that does not do the thing it is sold for.
Side effects and warning signs
Commonly reported
- Injection-site irritation
- Headache
- Very few reported effects, consistent with a compound that showed little activity in trials
Stop and get medical help
- No meaningful human safety signal has emerged, but neither has a meaningful efficacy signal
Sources
From the community
Discussion for this compound concentrates in r/Peptides.
No threads cached yet.
Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.